Curcumin extract for prevention of type 2 diabetes.
Abstract
OBJECTIVE
To assess the efficacy of curcumin in delaying development of type 2 diabetes mellitus (T2DM) in the prediabetic population.RESEARCH DESIGN AND METHODS
This randomized, double-blinded, placebo- controlled trial included subjects (n = 240) with criteria of prediabetes. All subjects were randomly assigned to receive either curcumin or placebo capsules for 9 months. To assess the T2DM progression after curcumin treatments and to determine the number of subjects progressing to T2DM, changes in β-cell functions (homeostasis model assessment [HOMA]-β, C-peptide, and proinsulin/insulin), insulin resistance (HOMA-IR), anti-inflammatory cytokine (adiponectin), and other parameters were monitored at the baseline and at 3-, 6-, and 9-month visits during the course of intervention.RESULTS
After 9 months of treatment, 16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the curcumin-treated group. In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (61.58 vs. 48.72; P < 0.01) and lower C-peptide (1.7 vs. 2.17; P < 0.05). The curcumin-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04; P < 0.001) and higher adiponectin (22.46 vs. 18.45; P < 0.05) when compared with the placebo group.CONCLUSIONS
A 9-month curcumin intervention in a prediabetic population significantly lowered the number of prediabetic individuals who eventually developed T2DM. In addition, the curcumin treatment appeared to improve overall function of β-cells, with very minor adverse effects. Therefore, this study demonstrated that the curcumin intervention in a prediabetic population may be beneficial.Links
Authors+Show Affiliations
,Division of Endocrinology and Metabolism, Faculty of Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakornnayok, Thailand. somlukc@hotmail.com
, , ,Source
Diabetes care 35:11 2012 Nov pg 2121-7
MeSH
CurcuminDiabetes Mellitus, Type 2
Double-Blind Method
Female
Humans
Male
Middle Aged
Plant Extracts
Prediabetic State
Treatment Outcome
Pub Type(s)
Journal ArticleRandomized Controlled Trial
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
22773702
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Curcumin extract for prevention of type 2 diabetes.
AU - Chuengsamarn,Somlak,
AU - Rattanamongkolgul,Suthee,
AU - Luechapudiporn,Rataya,
AU - Phisalaphong,Chada,
AU - Jirawatnotai,Siwanon,
Y1 - 2012/07/06/
PY - 2012/7/10/entrez
PY - 2012/7/10/pubmed
PY - 2013/4/18/medline
SP - 2121
EP - 7
JF - Diabetes care
JO - Diabetes Care
VL - 35
IS - 11
N2 - OBJECTIVE: To assess the efficacy of curcumin in delaying development of type 2 diabetes mellitus (T2DM) in the prediabetic population. RESEARCH DESIGN AND METHODS: This randomized, double-blinded, placebo- controlled trial included subjects (n = 240) with criteria of prediabetes. All subjects were randomly assigned to receive either curcumin or placebo capsules for 9 months. To assess the T2DM progression after curcumin treatments and to determine the number of subjects progressing to T2DM, changes in β-cell functions (homeostasis model assessment [HOMA]-β, C-peptide, and proinsulin/insulin), insulin resistance (HOMA-IR), anti-inflammatory cytokine (adiponectin), and other parameters were monitored at the baseline and at 3-, 6-, and 9-month visits during the course of intervention. RESULTS: After 9 months of treatment, 16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the curcumin-treated group. In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (61.58 vs. 48.72; P < 0.01) and lower C-peptide (1.7 vs. 2.17; P < 0.05). The curcumin-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04; P < 0.001) and higher adiponectin (22.46 vs. 18.45; P < 0.05) when compared with the placebo group. CONCLUSIONS: A 9-month curcumin intervention in a prediabetic population significantly lowered the number of prediabetic individuals who eventually developed T2DM. In addition, the curcumin treatment appeared to improve overall function of β-cells, with very minor adverse effects. Therefore, this study demonstrated that the curcumin intervention in a prediabetic population may be beneficial.
SN - 1935-5548
UR - https://www.unboundmedicine.com/medline/citation/22773702/abstract/Curcumin_Extract_for_Prevention_of_Type_2_Diabetes_
L2 - http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=22773702
DB - PRIME
DP - Unbound Medicine
ER -
